The present invention concerns a food composition for use in preventing nutrients' inadequacies in lactating women with high protein type dietary pattern.

The present technology generally relates to compositions comprising at least one purified cannabinoid or a derivative thereof, and at least one functional fragrance. The present technology also generally relates to methods of using the compositions for, inter alia, improving sleep, for treating insomnia and/or related sleep disorders.

The present technology generally relates to compositions comprising at least one purified cannabinoid or a derivative thereof, and at least one functional fragrance. The present technology also generally relates to methods of using the compositions for, inter alia, improving sleep, for treating insomnia and/or related sleep disorders.

The lyophilized formulation of stem cell-derived exosomes and the anti-inflammatory composition including the same as an active ingredient is able to stabilize stem cell-derived exosomes and exhibit excellent anti-inflammatory effects, and particularly, exhibit remarkable anti-inflammatory effects as compared with not-lyophilized stem cell-derived exosomes isolated and purified from conditioned media of stem cells. Therefore, the lyophilized formulation of stem cell-derived exosomes and the anti-inflammatory composition including the same as an active ingredient is able to effectively prevent, suppress, alleviate, ameliorate or treat inflammatory response or inflammatory diseases.

The lyophilized formulation of stem cell-derived exosomes and the anti-inflammatory composition including the same as an active ingredient is able to stabilize stem cell-derived exosomes and exhibit excellent anti-inflammatory effects, and particularly, exhibit remarkable anti-inflammatory effects as compared with not-lyophilized stem cell-derived exosomes isolated and purified from conditioned media of stem cells. Therefore, the lyophilized formulation of stem cell-derived exosomes and the anti-inflammatory composition including the same as an active ingredient is able to effectively prevent, suppress, alleviate, ameliorate or treat inflammatory response or inflammatory diseases.

The disclosed invention relates to a chemical composition that can be taken orally and supplements an unhealthy diet and lifestyle. In one aspect of the invention the chemical composition includes Retinol Palmitate, Thiamine, Riboflavin, Niacin, Nicotinamide mononucleotide (NMN), Pyridoxal, Folic Acid, Cyanocobalamin, Cholecalciferol, Zinc, Manganese, Copper, Calcium, Magnesium, Iron, L-Selenomethionine, Lysine, Phenylalanine, L-Threonine, L-Methionine, L-Histidine, L-Tryptophan, L-Leucine, L-Isoleucine, L-Valine, Cinnamon Bark Powder, and Curcumin.

The disclosed invention relates to a chemical composition that can be taken orally and supplements an unhealthy diet and lifestyle. In one aspect of the invention the chemical composition includes Retinol Palmitate, Thiamine, Riboflavin, Niacin, Nicotinamide mononucleotide (NMN), Pyridoxal, Folic Acid, Cyanocobalamin, Cholecalciferol, Zinc, Manganese, Copper, Calcium, Magnesium, Iron, L-Selenomethionine, Lysine, Phenylalanine, L-Threonine, L-Methionine, L-Histidine, L-Tryptophan, L-Leucine, L-Isoleucine, L-Valine, Cinnamon Bark Powder, and Curcumin.

The invention relates to a composition for use in the prevention or treatment of Salmonellosis in animals, said use comprising administering the composition to the animal, wherein the composition contains at least 0.01% by weight of dry matter of rhamnogalacturonan I (RG-I) polysaccharides having a molecular weight of more than 2 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1.fwdarw.4)-galacturonic-alpha(1.fwdarw.2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 50:1 to 1:1. The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused by Salmonella strains with resistance to antibiotics.

This invention relates to a method and composition for inducing allergen tolerance in a patient suffering from an atopic allergy or allergic asthma; hence reducing allergy symptoms in these patients.

This invention relates to a method and composition for inducing allergen tolerance in a patient suffering from an atopic allergy or allergic asthma; hence reducing allergy symptoms in these patients.